Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes

Clinical Lymphoma

Volumn 6, Issue 1, 2005, Pages 52-55

  Musto, Pellegrino ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYTOKINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEMOGLOBIN; INTERLEUKIN 3; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID; THALIDOMIDE; PEGYLATED ERYTHROPOIETIN; RECOMBINANT HORMONE; UNCLASSIFIED DRUG;

ANEMIA; BIOLOGICAL ACTIVITY; BLOOD TRANSFUSION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG USE; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; HUMAN; IRON DEFICIENCY; MYELODYSPLASTIC SYNDROME; NOTE; PREDICTION; PURE RED CELL ANEMIA; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; THROMBOEMBOLISM; ARTICLE; COMBINATION CHEMOTHERAPY; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG POTENTIATION; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FATIGUE; IRON OVERLOAD; MAINTENANCE DRUG DOSE; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT;

EID: 22944487687     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.029     Document Type: Note

References (34)

1. Stein RS. The role of erythropoietin in the anemia of myelodysplastic syndromes. Clin Lymphoma 2003; 4(suppl 1):S36-S40.
2. Italian Cooperative Study Group for r-Hu-Epo in Myelodysplastic Syndromes. A randomized, double-blind, placebo-controlled study with subcutaneous human erythropoietin in patients with low risk myelodysplastic syndromes. Br J Haematol 1998; 103:1070-1074.
3. Terpos E, Mugiou A, Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response race in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002; 118:174-180.
4. Hast R, Wallvik J, Folin A, et al. Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leuk Res 2001; 25:13-18.
5. Musto P, Falcone A, Sanpaolo G, et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 2003; 122: 269-271.
6. Aloe-Spiriti MA, Petri MC, Latagliata R, et al, for The Italian Fatigue/QoL, MDS Cooperative Group. Effects of 40.000 IU bi-weekly induction dose of Epoetin alpha followed by 40.000 IU once weekly in low risk myelodysplastic syndrome patients. Ann Hematol, in press.
7. Musto P, Lanza F, Balleari E, et al. Darbepoetin-alpha for the treatment of anemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol, in press.
8. Hellstrom-Lindberg E. Efficacy of eryrhropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients fron 17 studies. Br J Haematol 1995; 89:67-71.
9. Musto P, Modoni S, Alicino G, et al. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. Haematologica 1994; 79:493-499.
10. Quint L, Giraudier S, Casadevall N. Pure red cella aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins. Br J Haematol 2004; 124:842.
11. Wallvik J, Stenke L, Bernell P, et al. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol 2002; 68:180-185.
12. Cerami A, Brines ML, Ghezzi P, et al. Effects of epoetin alpha on the central nervous system. Semin Oncol 2001; 28 (suppl 8):66-70.
13. Mittelman M, Neumann D, Peled A. Erythropoietin induces tumor regression and anti-tumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001; 98:5181-5186.
14. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effect of epoetin-alpha on hematological parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blinded, placebo-controlled study. J Clin Oncol 2001; 19:2865-2874.
15. Musto P, Sanpaolo G, D'Arena G, et al. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica 2001; 86:44-51.
16. Kasper C, Zahner J, Sayer HG. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol 2002; 128:497-502.
17. Tefferi A, Elliot MA, Steensma DP, et al. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndromes. Leuk Res 2001; 25:1853-1855.
18. Grossi A, Musto P, Santini V, et al. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. Haematologica 2002; 87:322-823.
19. Stasi R, Brunetti M, Terzoli E, et al. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 2002; 99:1578-1584.
20. Musto P, Cascavilla N, Falcone A, et al. Combination of erythropoietin and thalidomide: no evidence of synergistic effect on anemia of patients with myelodysplastic syndromes. Haematologica 2004; 89(suppl 6):83.
21. Steurer M, Sudmeier I, Stauder R et al. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 2003; 121:101-103.
22. Negrin RS, Stein R, Vardiman J, et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating Factor in combination with erythropoietin. Blood 1993; 82:737-743.
23. Hellstrom-Lindberg E, Birgegard G, Carlsson M, et al. A combination of granulocyce colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 1993; 11:221-228.
24. Imamura M, Kobayashi M, Kobayashi S, et al. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol 1994; 68:163-166.
25. Musto P, Falcone A, Catalano L, et al. Granulocyte colony stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone? Blood 1994; 82:1687-1688.
26. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996; 87:4076-4081.
27. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of the anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized, phase II study and long term follow-up of 71 patients. Blood 1998; 92:68-75.
28. Remacha AF, Arrizabalaga B, Villegas A, et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica 1999; 84:1058-1063.
29. Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000; 109:367-375.
30. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004; 104:321-327.
31. Hellstrom-Lindberg E, Gubrandsen N, Lindberg G, et al. A validated decision model for treating the anaernia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120:1037-1046.
32. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100:2303-2320.
33. Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of myelodysplastic syndromes: a statement from tha Italian Society of Hematology. Haematologica 2002; 87:1286-1306.
34. Bowen D, Culligan D, Jewitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120:187-200.